Literature DB >> 10030266

Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy.

E Dale1, D R Olsen, S D Fosså.   

Abstract

PURPOSE: Radiation therapy of deep-sited tumours will always result in normal tissue doses to some extent. The aim of this study was to calculate different risk estimates of late effects in the rectum for a group of cancer prostate patients treated with conformal radiation therapy (CRT) and correlate these estimates with the occurrences of late effects. Since the rectum is a hollow organ, several ways of generating dose-volume distributions over the organ are possible, and we wanted to investigate two of them. METHODS AND MATERIALS: A mathematical model, known as the Lyman-Kutcher model, conventionally used to estimate normal tissue complication probabilities (NTCP) associated with radiation therapy, was applied to a material of 52 cancer prostate patients. The patients were treated with a four field box technique, with the rectum as organ at risk. Dose-volume histograms (DVH) were generated for the whole rectum (including the cavity) and of the rectum wall. One to two years after the treatment, the patients completed a questionnaire concerning bowel (rectum) related morbidity quantifying the extent of late effects.
RESULTS: A correlation analysis using Spearman's rank correlation coefficient, for NTCP values calculated from the DVHs and the patients' scores, gave correlation coefficients which were not statistically significant at the p<0.01 level. The correlation coefficients based on histograms of the whole rectum were larger than those derived from histograms of the rectum wall. Also, simpler descriptive measures as Dmax, of the whole rectum, correlated better to observed late toxicity than Dmax derived from histograms of the rectum wall. Correlation coefficients from "high-dose" measures were larger than those calculated from the NTCP values. Accordingly, as the volume parameter of the Lyman-Kutcher model was reduced, raising the impact of small high-dose volumes on the NTCP values, the correlation between observed effects and NTCP values became significant at p<0.01 level.
CONCLUSIONS: 1) High-dose levels corresponding to small volume fractions of the cumulative dose-volume histograms were best correlated with the occurrences of late effects in the rectum as measured with questionnaires. This is compatible with a more serial organisation of the rectal tissue architecture than previously reported. 2) Reducing the Lyman-Kutcher model's volume parameter, thus allowing small high-dose regions to determine the NTCP, improved the correlation, but not beyond that of high-dose levels corresponding to small volume fractions of the cumulative dose-volume histograms.

Entities:  

Mesh:

Year:  1999        PMID: 10030266     DOI: 10.1016/s0360-3016(98)00400-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

2.  Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.

Authors:  Vittoria D'Avino; Giuseppe Palma; Raffaele Liuzzi; Manuel Conson; Francesca Doria; Marco Salvatore; Roberto Pacelli; Laura Cella
Journal:  Radiat Oncol       Date:  2015-04-08       Impact factor: 3.481

3.  Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis.

Authors:  Ashesh B Jani; Christopher M Hand; Charles A Pelizzari; John C Roeske; Lani Krauz; Srinivasan Vijayakumar
Journal:  BMC Cancer       Date:  2003-05-13       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.